DK2596801T3 - RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT - Google Patents

RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT Download PDF

Info

Publication number
DK2596801T3
DK2596801T3 DK13154196.3T DK13154196T DK2596801T3 DK 2596801 T3 DK2596801 T3 DK 2596801T3 DK 13154196 T DK13154196 T DK 13154196T DK 2596801 T3 DK2596801 T3 DK 2596801T3
Authority
DK
Denmark
Prior art keywords
mva
mher2
mice
tumor
antigen
Prior art date
Application number
DK13154196.3T
Other languages
Danish (da)
English (en)
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK2596801T3 publication Critical patent/DK2596801T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK13154196.3T 2006-10-06 2007-10-05 RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT DK2596801T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85003106P 2006-10-06 2006-10-06
EP07839307.1A EP2073837B1 (en) 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer

Publications (1)

Publication Number Publication Date
DK2596801T3 true DK2596801T3 (en) 2018-08-13

Family

ID=39283388

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13154196.3T DK2596801T3 (en) 2006-10-06 2007-10-05 RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
DK07839307.1T DK2073837T3 (da) 2006-10-06 2007-10-05 Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07839307.1T DK2073837T3 (da) 2006-10-06 2007-10-05 Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer

Country Status (11)

Country Link
US (2) US7807146B2 (enExample)
EP (2) EP2073837B1 (enExample)
JP (2) JP5964540B2 (enExample)
AU (1) AU2007307080B2 (enExample)
CA (1) CA2665068C (enExample)
DK (2) DK2596801T3 (enExample)
ES (1) ES2500465T3 (enExample)
IL (1) IL197633A (enExample)
NZ (2) NZ575388A (enExample)
PT (1) PT2073837E (enExample)
WO (1) WO2008045346A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421151C (en) * 2000-11-23 2013-07-02 Bavarian Nordic A/S Modified vaccinia ankara virus variant
DK2596801T3 (en) * 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
WO2012059376A1 (en) * 2010-11-02 2012-05-10 Telefonaktiebolaget L M Ericsson (Publ) Methods and devices for media description delivery
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
AU2013331328B2 (en) * 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
WO2015000936A1 (en) 2013-07-03 2015-01-08 Koninklijke Kpn N.V. Streaming of segmented content
ES2693213T3 (es) 2013-10-23 2018-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epítopos agonistas de HLA-A24 de oncoproteína MUC1-C y composiciones y métodos de uso
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3706768A4 (en) * 2017-11-06 2021-08-25 Memorial Sloan Kettering Cancer Center USE OF THE HEAT-INACTIVATED VACCINE VIRUS AS A VACCINE IMMUNE ADJUDENT
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DE19729279A1 (de) 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
HK1039749B (zh) * 1998-10-05 2007-10-05 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
CA2421151C (en) 2000-11-23 2013-07-02 Bavarian Nordic A/S Modified vaccinia ankara virus variant
WO2003026581A2 (en) * 2001-09-26 2003-04-03 Intermune, Inc. Pharmaceutical compositions and methods for treating cancer
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
AU2003297155B2 (en) * 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
CN1511549A (zh) * 2002-12-27 2004-07-14 张小丽 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2004103301A2 (en) * 2003-05-16 2004-12-02 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US7763452B2 (en) 2003-06-25 2010-07-27 Bn Immunotherapeutics, Inc. Purification of HER-2 variants
EP1641819B1 (en) * 2003-06-25 2009-04-22 BN ImmunoTherapeutics, Inc. Purification of her-2 variants
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
DK1855720T4 (da) 2005-02-23 2023-07-24 Bavarian Nordic As Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer
DK2596801T3 (en) 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT

Also Published As

Publication number Publication date
US8313740B2 (en) 2012-11-20
ES2500465T3 (es) 2014-09-30
WO2008045346A3 (en) 2009-06-04
EP2073837A2 (en) 2009-07-01
AU2007307080B2 (en) 2014-01-09
CA2665068C (en) 2016-01-05
US7807146B2 (en) 2010-10-05
WO2008045346A2 (en) 2008-04-17
DK2073837T3 (da) 2014-09-29
JP6124822B2 (ja) 2017-05-10
NZ575388A (en) 2012-03-30
PT2073837E (pt) 2014-09-22
EP2073837B1 (en) 2014-06-25
JP2014129416A (ja) 2014-07-10
IL197633A (en) 2017-03-30
EP2596801A1 (en) 2013-05-29
NZ597998A (en) 2013-08-30
CA2665068A1 (en) 2008-04-17
US20110008294A1 (en) 2011-01-13
AU2007307080A1 (en) 2008-04-17
US20080213302A1 (en) 2008-09-04
JP2010505850A (ja) 2010-02-25
EP2596801B1 (en) 2018-05-02
JP5964540B2 (ja) 2016-08-03
IL197633A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
DK2596801T3 (en) RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
JP7368305B2 (ja) 腫瘍抗原を発現するポックスウイルス及びtim-3に対するモノクローナル抗体を用いた癌治療のための併用療法
CA2702586C (en) Use of mva to treat prostate cancer
AU2015259510B2 (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
RU2714142C2 (ru) Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки
US20150283220A1 (en) Methods and compositions for the treatment of cancer
HK1149709B (en) Use of mva to treat prostate cancer